10 Questions For A Big Pharma Data Captain
This article was originally published in Scrip
James Weatherall is the head of the Advanced Analytics Centre set up by AstraZeneca two years ago. Dr Weatherall argues that pharma needs to get on top of its data strategy and rationalize its efforts if it is to take full advantage of the tremendous opportunity that big data, data science and data analytics offer to the industry. He spoke to Scrip's Eleanor Malone about his work at AstraZeneca, where industry is up to vis-à-vis big data, and the challenges and opportunities it will face in this arena in the coming years.
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.